LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 25

Search options

  1. Article: Oral Adelmidrol Administration Up-Regulates Palmitoylethanolamide Production in Mice Colon and Duodenum through a PPAR-γ Independent Action.

    Del Re, Alessandro / Palenca, Irene / Seguella, Luisa / Pesce, Marcella / Corpetti, Chiara / Steardo, Luca / Rurgo, Sara / Sarnelli, Giovanni / Esposito, Giuseppe

    Metabolites

    2022  Volume 12, Issue 5

    Abstract: Adelmidrol is a promising palmitoylethanolamide (PEA) analog which displayed up-and-coming anti-inflammatory properties in several inflammatory conditions. Recent studies demonstrated that Adelmidrol is an in vitro enhancer of PEA endogenous production, ... ...

    Abstract Adelmidrol is a promising palmitoylethanolamide (PEA) analog which displayed up-and-coming anti-inflammatory properties in several inflammatory conditions. Recent studies demonstrated that Adelmidrol is an in vitro enhancer of PEA endogenous production, through the so called "entourage" effect. The present study investigated the ability of Adelmidrol (1 and 10 mg/Kg per os) to increase the endogenous level of PEA in the duodenum and colon of mice after 21-day oral administration in the presence and absence of PPAR-γ inhibitor (1 mg/kg). The level of PEA was analyzed by HPLC-MS. The expression of PEA-related enzymatic machinery was evaluated by western blot and RT-PCR analysis. Our findings demonstrated that Adelmidrol significantly increased PEA levels in the duodenum and colon in a dose/time-dependent manner. We also revealed that Adelmidrol up regulated the enzymatic machinery responsible for PEA metabolism and catabolism. Interestingly, the use of the selective irreversible PPAR-γ antagonist did not affect either PEA intestinal levels or expression/transcription of PEA metabolic enzymes following Adelmidrol administration. The "entourage effect" with Adelmidrol as an enhancer of PEA was thus PPAR-γ-independent. The findings suggest that Adelmidrol can maximize a PEA therapeutic-based approach in several intestinal morbidities.
    Language English
    Publishing date 2022-05-19
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662251-8
    ISSN 2218-1989
    ISSN 2218-1989
    DOI 10.3390/metabo12050457
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Oral Immunization with

    Sarnelli, Giovanni / Del Re, Alessandro / Pesce, Marcella / Lu, Jie / Esposito, Giovanni / Sanseverino, Walter / Corpetti, Chiara / Basili Franzin, Silvia / Seguella, Luisa / Palenca, Irene / Rurgo, Sara / De Palma, Fatima Domenica Elisa / Zilli, Aurora / Esposito, Giuseppe

    Biomolecules

    2023  Volume 13, Issue 3

    Abstract: As of October 2022, the COVID-19 pandemic continues to pose a major public health conundrum, with increased rates of symptomatic infections in vaccinated individuals. An ideal vaccine candidate for the prevention of outbreaks should be rapidly scalable, ... ...

    Abstract As of October 2022, the COVID-19 pandemic continues to pose a major public health conundrum, with increased rates of symptomatic infections in vaccinated individuals. An ideal vaccine candidate for the prevention of outbreaks should be rapidly scalable, easy to administer, and able to elicit a potent mucosal immunity. Towards this aim, we proposed an engineered
    MeSH term(s) Humans ; Animals ; Mice ; Spike Glycoprotein, Coronavirus/genetics ; Escherichia coli/genetics ; COVID-19 Vaccines ; Antibody Formation ; Pandemics ; COVID-19/prevention & control ; SARS-CoV-2 ; Immunization/methods ; Antibodies, Viral
    Chemical Substances spike protein, SARS-CoV-2 ; Spike Glycoprotein, Coronavirus ; COVID-19 Vaccines ; Antibodies, Viral
    Language English
    Publishing date 2023-03-21
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2701262-1
    ISSN 2218-273X ; 2218-273X
    ISSN (online) 2218-273X
    ISSN 2218-273X
    DOI 10.3390/biom13030569
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The potential of cannabidiol in the COVID-19 pandemic.

    Esposito, Giuseppe / Pesce, Marcella / Seguella, Luisa / Sanseverino, Walter / Lu, Jie / Corpetti, Chiara / Sarnelli, Giovanni

    British journal of pharmacology

    2020  Volume 177, Issue 21, Page(s) 4967–4970

    Abstract: Identifying drugs effective in the new coronavirus disease 2019 (COVID-19) is crucial, pending a vaccine against SARS-CoV2. We suggest the hypothesis that cannabidiol (CBD), a non-psychotropic phytocannabinoid, has the potential to limit the severity and ...

    Abstract Identifying drugs effective in the new coronavirus disease 2019 (COVID-19) is crucial, pending a vaccine against SARS-CoV2. We suggest the hypothesis that cannabidiol (CBD), a non-psychotropic phytocannabinoid, has the potential to limit the severity and progression of the disease for several reasons:- (a) High-cannabidiol Cannabis sativa extracts are able to down-regulate the expression of the two key receptors for SARS-CoV2 in several models of human epithelia, (b) cannabidiol exerts a wide range of immunomodulatory and anti-inflammatory effects and it can mitigate the uncontrolled cytokine production responsible for acute lung injury, (c) being a PPARγ agonist, it can display a direct antiviral activity and (d) PPARγ agonists are regulators of fibroblast/myofibroblast activation and can inhibit the development of pulmonary fibrosis, thus ameliorating lung function in recovered patients. We hope our hypothesis, corroborated by preclinical evidence, will inspire further targeted studies to test cannabidiol as a support drug against the COVID-19 pandemic. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
    MeSH term(s) Animals ; Betacoronavirus/drug effects ; Betacoronavirus/isolation & purification ; COVID-19 ; Cannabidiol/administration & dosage ; Cannabidiol/isolation & purification ; Cannabidiol/pharmacology ; Cannabis/chemistry ; Coronavirus Infections/drug therapy ; Coronavirus Infections/virology ; Disease Progression ; Humans ; Pandemics ; Plant Extracts/chemistry ; Plant Extracts/pharmacology ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/virology ; SARS-CoV-2 ; Severity of Illness Index ; COVID-19 Drug Treatment
    Chemical Substances Plant Extracts ; Cannabidiol (19GBJ60SN5)
    Keywords covid19
    Language English
    Publishing date 2020-07-16
    Publishing country England
    Document type Journal Article
    ZDB-ID 80081-8
    ISSN 1476-5381 ; 0007-1188
    ISSN (online) 1476-5381
    ISSN 0007-1188
    DOI 10.1111/bph.15157
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPARγ-dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line.

    Corpetti, Chiara / Del Re, Alessandro / Seguella, Luisa / Palenca, Irene / Rurgo, Sara / De Conno, Barbara / Pesce, Marcella / Sarnelli, Giovanni / Esposito, Giuseppe

    Phytotherapy research : PTR

    2021  Volume 35, Issue 12, Page(s) 6893–6903

    Abstract: Given the abundancy of angiotensin converting enzyme 2 (ACE-2) receptors density, beyond the lung, the intestine is considered as an alternative site of infection and replication for severe acute respiratory syndrome by coronavirus type 2 (SARS-CoV-2). ... ...

    Abstract Given the abundancy of angiotensin converting enzyme 2 (ACE-2) receptors density, beyond the lung, the intestine is considered as an alternative site of infection and replication for severe acute respiratory syndrome by coronavirus type 2 (SARS-CoV-2). Cannabidiol (CBD) has recently been proposed in the management of coronavirus disease 2019 (COVID-19) respiratory symptoms because of its anti-inflammatory and immunomodulatory activity exerted in the lung. In this study, we demonstrated the in vitro PPAR-γ-dependent efficacy of CBD (10
    MeSH term(s) COVID-19 ; Caco-2 Cells ; Cannabidiol/pharmacology ; Caspase 1 ; Cytokines ; Humans ; Inflammation ; NLR Family, Pyrin Domain-Containing 3 Protein ; PPAR gamma ; SARS-CoV-2/drug effects ; Signal Transduction/drug effects ; Spike Glycoprotein, Coronavirus/immunology ; Toll-Like Receptor 4
    Chemical Substances Cytokines ; NLR Family, Pyrin Domain-Containing 3 Protein ; PPAR gamma ; Spike Glycoprotein, Coronavirus ; TLR4 protein, human ; Toll-Like Receptor 4 ; spike protein, SARS-CoV-2 ; Cannabidiol (19GBJ60SN5) ; Caspase 1 (EC 3.4.22.36)
    Language English
    Publishing date 2021-10-12
    Publishing country England
    Document type Journal Article
    ZDB-ID 639136-9
    ISSN 1099-1573 ; 0951-418X
    ISSN (online) 1099-1573
    ISSN 0951-418X
    DOI 10.1002/ptr.7302
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Next-Generation Probiotics for Inflammatory Bowel Disease.

    Pesce, Marcella / Seguella, Luisa / Del Re, Alessandro / Lu, Jie / Palenca, Irene / Corpetti, Chiara / Rurgo, Sara / Sanseverino, Walter / Sarnelli, Giovanni / Esposito, Giuseppe

    International journal of molecular sciences

    2022  Volume 23, Issue 10

    Abstract: Engineered probiotics represent a cutting-edge therapy in intestinal inflammatory disease (IBD). Genetically modified bacteria have provided a new strategy to release therapeutically operative molecules in the intestine and have grown into promising new ... ...

    Abstract Engineered probiotics represent a cutting-edge therapy in intestinal inflammatory disease (IBD). Genetically modified bacteria have provided a new strategy to release therapeutically operative molecules in the intestine and have grown into promising new therapies for IBD. Current IBD treatments, such as corticosteroids and immunosuppressants, are associated with relevant side effects and a significant proportion of patients are dependent on these therapies, thus exposing them to the risk of relevant long-term side effects. Discovering new and effective therapeutic strategies is a worldwide goal in this research field and engineered probiotics could potentially provide a viable solution. This review aims at describing the proceeding of bacterial engineering and how genetically modified probiotics may represent a promising new biotechnological approach in IBD treatment.
    MeSH term(s) Bacteria ; Chronic Disease ; Humans ; Inflammatory Bowel Diseases/microbiology ; Inflammatory Bowel Diseases/therapy ; Intestines/microbiology ; Probiotics/therapeutic use
    Language English
    Publishing date 2022-05-13
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms23105466
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The potential of cannabidiol in the COVID-19 pandemic

    Esposito, Giuseppe / Pesce, Marcella / Seguella, Luisa / Sanseverino, Walter / Lu, Jie / Corpetti, Chiara / Sarnelli, Giovanni

    a hypothesis letter

    2020  

    Keywords covid19
    Language English
    Publishing country it
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: The potential of cannabidiol in the COVID‐19 pandemic

    Esposito, Giuseppe / Pesce, Marcella / Seguella, Luisa / Sanseverino, Walter / Lu, Jie / Corpetti, Chiara / Sarnelli, Giovanni

    British Journal of Pharmacology

    2020  Volume 177, Issue 21, Page(s) 4967–4970

    Keywords Pharmacology ; covid19
    Language English
    Publisher Wiley
    Publishing country us
    Document type Article ; Online
    ZDB-ID 80081-8
    ISSN 1476-5381 ; 0007-1188
    ISSN (online) 1476-5381
    ISSN 0007-1188
    DOI 10.1111/bph.15157
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article: Nutraceuticals and Diet Supplements in Crohn's Disease: A General Overview of the Most Promising Approaches in the Clinic.

    De Conno, Barbara / Pesce, Marcella / Chiurazzi, Martina / Andreozzi, Marta / Rurgo, Sara / Corpetti, Chiara / Seguella, Luisa / Del Re, Alessandro / Palenca, Irene / Esposito, Giuseppe / Sarnelli, Giovanni

    Foods (Basel, Switzerland)

    2022  Volume 11, Issue 7

    Abstract: Crohn's disease (CD) is a chronic inflammatory gastrointestinal disorder requiring lifelong medications. The currently approved drugs for CD are associated with relevant side effects and several studies suggest an increased use of nutraceuticals among CD ...

    Abstract Crohn's disease (CD) is a chronic inflammatory gastrointestinal disorder requiring lifelong medications. The currently approved drugs for CD are associated with relevant side effects and several studies suggest an increased use of nutraceuticals among CD patients, seeking for what is perceived as a more "natural" approach in controlling this highly morbid condition. Nutraceuticals are foods or foods' components with beneficial health properties that could aid in CD treatment for their anti-inflammatory, analgesic and immunoregulatory activities that come along with safety, high tolerability, easy availability and affordability. Depending on their biological effect, nutraceuticals' support could be employed in different subsets of CD patients, both those with active disease, as adjunctive immunomodulatory therapies, and/or in quiescent disease to provide symptomatic relief in patients with residual functional symptoms. Despite the increasing interest of the general public, both limited research and lack of education from healthcare professionals regarding their real clinical effectiveness account for the increasing number of patients turning to unconventional sources. Professionals should recognize their widespread use and the evidence base for or against their efficacy to properly counsel IBD patients. Overall, nutraceuticals appear to be safe complements to conventional therapies; nonetheless, little quality evidence supports a positive impact on underlying inflammatory activity.
    Language English
    Publishing date 2022-04-04
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2704223-6
    ISSN 2304-8158
    ISSN 2304-8158
    DOI 10.3390/foods11071044
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Cannabidiol inhibits SARS‐Cov‐2 spike (S) protein‐induced cytotoxicity and inflammation through a PPARγ‐dependent TLR4/NLRP3/Caspase‐1 signaling suppression in Caco‐2 cell line

    Corpetti, Chiara / Del Re, Alessandro / Seguella, Luisa / Palenca, Irene / Rurgo, Sara / De Conno, Barbara / Pesce, Marcella / Sarnelli, Giovanni / Esposito, Giuseppe

    Phytotherapy research. 2021 Dec., v. 35, no. 12

    2021  

    Abstract: Given the abundancy of angiotensin converting enzyme 2 (ACE‐2) receptors density, beyond the lung, the intestine is considered as an alternative site of infection and replication for severe acute respiratory syndrome by coronavirus type 2 (SARS‐CoV‐2). ... ...

    Abstract Given the abundancy of angiotensin converting enzyme 2 (ACE‐2) receptors density, beyond the lung, the intestine is considered as an alternative site of infection and replication for severe acute respiratory syndrome by coronavirus type 2 (SARS‐CoV‐2). Cannabidiol (CBD) has recently been proposed in the management of coronavirus disease 2019 (COVID‐19) respiratory symptoms because of its anti‐inflammatory and immunomodulatory activity exerted in the lung. In this study, we demonstrated the in vitro PPAR‐γ‐dependent efficacy of CBD (10⁻⁹‐10⁻⁷ M) in preventing epithelial damage and hyperinflammatory response triggered by SARS‐CoV‐2 spike protein (SP) in a Caco‐2 cells. Immunoblot analysis revealed that CBD was able to reduce all the analyzed proinflammatory markers triggered by SP incubation, such as tool‐like receptor 4 (TLR‐4), ACE‐2, family members of Ras homologues A‐GTPase (RhoA‐GTPase), inflammasome complex (NLRP3), and Caspase‐1. CBD caused a parallel inhibition of interleukin 1 beta (IL‐1β), IL‐6, tumor necrosis factor alpha (TNF‐α), and IL‐18 by enzyme‐linked immunosorbent assay (ELISA) assay. By immunofluorescence analysis, we observed increased expression of tight‐junction proteins and restoration of transepithelial electrical resistance (TEER) following CBD treatment, as well as the rescue of fluorescein isothiocyanate (FITC)–dextran permeability induced by SP. Our data indicate, in conclusion, that CBD is a powerful inhibitor of SP protein enterotoxicity in vitro.
    Keywords COVID-19 infection ; Severe acute respiratory syndrome coronavirus 2 ; cannabidiol ; caspase-1 ; cytotoxicity ; electrical resistance ; enzyme-linked immunosorbent assay ; epithelium ; fluorescein ; fluorescent antibody technique ; human cell lines ; immunomodulators ; inflammasomes ; inflammation ; interleukin-18 ; interleukin-6 ; intestines ; isothiocyanates ; lungs ; permeability ; phytotherapy ; research ; tumor necrosis factor-alpha
    Language English
    Dates of publication 2021-12
    Size p. 6893-6903.
    Publishing place John Wiley & Sons, Ltd.
    Document type Article
    Note JOURNAL ARTICLE
    ZDB-ID 639136-9
    ISSN 1099-1573 ; 0951-418X
    ISSN (online) 1099-1573
    ISSN 0951-418X
    DOI 10.1002/ptr.7302
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  10. Article ; Online: N-Palmitoyl-D-Glucosamine Inhibits TLR-4/NLRP3 and Improves DNBS-Induced Colon Inflammation through a PPAR-α-Dependent Mechanism.

    Palenca, Irene / Seguella, Luisa / Del Re, Alessandro / Franzin, Silvia Basili / Corpetti, Chiara / Pesce, Marcella / Rurgo, Sara / Steardo, Luca / Sarnelli, Giovanni / Esposito, Giuseppe

    Biomolecules

    2022  Volume 12, Issue 8

    Abstract: Similar to canine inflammatory enteropathy, inflammatory bowel disease (IBD) is a chronic idiopathic condition characterized by remission periods and recurrent flares in which diarrhea, visceral pain, rectal bleeding/bloody stools, and weight loss are ... ...

    Abstract Similar to canine inflammatory enteropathy, inflammatory bowel disease (IBD) is a chronic idiopathic condition characterized by remission periods and recurrent flares in which diarrhea, visceral pain, rectal bleeding/bloody stools, and weight loss are the main clinical symptoms. Intestinal barrier function alterations often persist in the remission phase of the disease without ongoing inflammatory processes. However, current therapies include mainly anti-inflammatory compounds that fail to promote functional symptoms-free disease remission, urging new drug discoveries to handle patients during this step of the disease. ALIAmides (ALIA, autacoid local injury antagonism) are bioactive fatty acid amides that recently gained attention because of their involvement in the control of inflammatory response, prompting the use of these molecules as plausible therapeutic strategies in the treatment of several chronic inflammatory conditions. N-palmitoyl-D-glucosamine (PGA), an under-researched ALIAmide, resulted in being safe and effective in preclinical models of inflammation and pain, suggesting its potential engagement in the treatment of IBD. In our study, we demonstrated that micronized PGA significantly and dose-dependently reduces colitis severity, improves intestinal mucosa integrity by increasing the tight junction proteins expression, and downregulates the TLR-4/NLRP3/iNOS pathway via PPAR-α receptors signaling in DNBS-treated mice. The possibility of clinically exploiting micronized PGA as support for the treatment and prevention of inflammation-related changes in IBD patients would represent an innovative, effective, and safe strategy.
    MeSH term(s) Animals ; Colitis/chemically induced ; Colitis/drug therapy ; Dinitrofluorobenzene/analogs & derivatives ; Dogs ; Glucosamine ; Inflammation/drug therapy ; Inflammatory Bowel Diseases/drug therapy ; Mice ; NLR Family, Pyrin Domain-Containing 3 Protein ; PPAR alpha ; Prostaglandins A ; Toll-Like Receptor 4
    Chemical Substances NLR Family, Pyrin Domain-Containing 3 Protein ; Nlrp3 protein, mouse ; PPAR alpha ; Prostaglandins A ; Toll-Like Receptor 4 ; 2,4-dinitrofluorobenzene sulfonic acid (143134-35-4) ; Dinitrofluorobenzene (D241E059U6) ; Glucosamine (N08U5BOQ1K)
    Language English
    Publishing date 2022-08-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2701262-1
    ISSN 2218-273X ; 2218-273X
    ISSN (online) 2218-273X
    ISSN 2218-273X
    DOI 10.3390/biom12081163
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top